Phase 3
Completed N=31
Project Q Pilot: Smoking Cessation for Light Smokers
Tobacco Use Cessation
Source: ClinicalTrials.gov NCT03416621 ↗
Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Feb 2021
Primary outcomePrimary: Number of Participants With Completion of at Least 2 Study Visits — 10; 7; 1 Participants
◆ Published Evidence
Emerging
5citations · ~1 / year
Cue-based treatment for light smokers: A proof of concept pilot.
Summary
The purpose of this pilot study is to evaluate the feasibility, acceptability, and preliminary efficacy of an intervention to promote smoking cessation among light smokers.
Linked Publications
-
Cue-based treatment for light smokers: A proof of concept pilot.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Completion of at Least 2 Study Visits |
10; 7; 1 | — |
| PRIMARY Number of Participants Who Rated the Intervention Acceptable |
23 | — |
| SECONDARY Number of Participants With Validated Cessation |
2; 0; 0 | — |
Eligibility Criteria
Inclusion Criteria
- Age: ≥18 years old
- Able to read and understand English or Spanish
- Cognitively able to provide informed consent
- Smoke 1-10 cigs/day on at least 4 days in the past month
- Express a desire to quit smoking in the next 30 days
- Access to a cell phone that can send and receive SMS text messages and take and send pictures
Exclusion Criteria
- Hypertension with a screening blood pressure over 160/100;
- Hypotension with a screening blood pressure of systolic 9 or > 0 on item #9
- Bulimia or anorexia;
- Pregnant or nursing;
- Use (within the past 30 days) of:
- Illegal drugs (or if the urine drug screen is positive for Cocaine, Amphetamine, Opiates, Methamphetamines, PCP, Benzodiazepines, or Barbiturates), unless prescribed for management of acute symptoms (tooth extraction, recent surgery);
- Experimental (investigational) drugs;
- Psychiatric medications including antidepressants (MAOIs, St. John's Wort), lithium, anti-psychotics, or any other medications that are known to affect smoking cessation (e.g. clonidine);
- Wellbutrin, bupropion, Zyban, Chantix, varenicline, nicotine patch, nicotine replacement therapy or any other smoking cessation aid.
- Use of cigars, cigarillos, pipes, Hookah, dissolvable nicotine, snuff, chewing tobacco , or e-cigarettes within the past 30 days;
- Positive result on AUDIT-C;
- Self-report of marijuana use ≥ 4 days per week;
- Significant adverse reaction to D-cycloserine in the past;
- Current or recent (in the past 30 days) participation in another smoking study at our Center or another research facility
Data sourced from ClinicalTrials.gov (NCT03416621) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.